Influence of antidepressants on ADAM10 platelet levels in Alzheimer's Disease

• Grant number: 12/01936-7
• Support Opportunities: Scholarships in Brazil - Scientific Initiation
• Start date: August 01, 2013
• End date: July 31, 2015
• Field of knowledge: Health Sciences - Medicine
• Principal Investigator: Márcia Regina Cominetti
• Grantee: Otávio Augusto Fernandes Marques Bianco
• Host Institution: Centro de Ciências Biológicas e da Saúde (CCBS). Universidade Federal de São Carlos (UFSCAR). São Carlos , SP, Brazil

Abstract

Alzheimer's Disease (AD) is the most common cause of dementia in people over 65 years in Brazil, and worldwide. About 50% of AD patients develop some depressive symptoms. Depression is a disease that has been gaining importance within the group of psychiatric disorders since about 20% of the population has suffered from this disease in the world. The elderly constitute a population portion largely affected by depression since the biopsychosocial changes that occur during this period of life - retirement, physical illness, change of social role, changing role within the family - cause great emotional imbalance. The treatment of this pathology is performed with antidepressants, which are divided into three main classes: tricyclic and tetracyclic drugs, MAO inhibitors, and serotonin reuptake inhibitors. In recent decades, AD has emerged from the obscurity of a rare disease to be considered a major public health problem among the elderly worldwide. To date, there is no cure for AD and early diagnosis is not yet well established. The pathological markers of AD are the formation of fibrillary tangles and senile plaques, generated by hiperosforilation of Tau protein and accumulation of ²-amyloid peptide (²A), respectively. This is formed by cleavage of amyloid precursor protein (APP) by beta and gamma-secretases. The ADAMs are alpha-secretase cleaving the APP working in a region that prevents the formation of ²A. Studies involving ADAM10 have demonstrated a decrease in its expression in patients with AD. A study by our research group also showed the same result. However, some of the subjects in this study were taking antidepressants. Therefore, the overall goal of this project is to investigate the influence of these drugs on the expression of ADAM10 protein. This is a case-control study, based on the assumptions of quantitative research and all ethical guidelines will be observed. Because of the relevance of depression incidence and prevalence in the elderly, it is necessary to study the effects of antidepressants on ADAM10 protein expression, thus establishing a baseline for the studies of this biomarker.(AU)

Scientific publications

(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)

FERNANDES MARQUES BIANCO, OTAVIO AUGUSTO; MANZINE, PATRICIA REGINA; CRISPIM NASCIMENTO, CARLA MANUELA; CARVALHO VALE, FRANCISCO ASSIS; IOST PAVARINI, SOFIA CRISTINA; COMINETTI, MARCIA REGINA. Serotoninergic antidepressants positively affect platelet ADAM10 expression in patients with Alzheimer's disease. INTERNATIONAL PSYCHOGERIATRICS, v. 28, n. 6, p. 939-944, JUN 2016. (10/09497-7, 12/01936-7, 14/21066-2, 13/06879-4, 12/08654-7)